RxDoctor Payments Data

Tara Drinnon

Family · Elizabethton, TNNPI 1659042000

Payments from drug & device makers

$2,496in general payments, 2019–2025

Across 132 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$599
  • Lilly USA, LLC$321
  • AstraZeneca$171
  • Boehringer Ingelheim$161
  • GSK$159
  • Lexicon Pharmaceuticals, Inc.$122
  • plus $962 from 21 others

What the payments were for

  • Food & beverage$2,496100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,496 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$15,751
Medicare patients
112
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$46,595
TrulicityDulaglutide23$23,750
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$15,494
FarxigaDapagliflozin Propanediol23$14,894
MounjaroTirzepatide13$14,506
Nurtec OdtRimegepant Sulfate11$12,771
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,352
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$8,864
SymbicortBudesonide/Formoterol Fumarate13$2,836
Albuterol Sulfate HfaAlbuterol Sulfate80$1,684
Omeprazole71$1,652
Gabapentin59$1,180
Atorvastatin Calcium103$1,054
Hydroxyzine Hcl24$1,006
Fluticasone Propionate55$700

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$65$46,59536 claims
Lilly USA, LLCTrulicity, Mounjaro$321$38,25636 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$171$27,08250 claims
GSKTrelegy Ellipta, Anoro Ellipta$159$24,35934 claims
PfizerNurtec Odt$120$12,77111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Elizabethton

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →